brain-penetrant mutant ALK kinase inhibitor
oral, Ph. I/II in ALK+ pre-treated cancers
undisclosed starting point, SBDD
Molecular Cancer Therapeutics
Turning Point Therapeutics, San Diego, US
TPX-0131
2. The Turning Point Therapeutics CNS-penetrant ALK kinase inhibitor, TPX-0131, is more potent in vitro than all 5 approved ALK inhibitors against WT-ALK and many ALK resistance mutations, including…